引用于 minsheng 在 2025-12-17, 下午7:41

应用我们的外星技术都可以消除. OBVIOUSLY ARE BETTER OFF, IF JAPANESE PEOPLE USE OUR ALIEN TECH. 因为有严重的代差和维度差, 绝大多数日本专业研究和医疗机构不理解我们在说什么和有什么. 

 

Here are several clinical trials and research efforts in Japan involving human cells—especially iPS (induced pluripotent stem cells) and related regenerative therapies. Many of these are registered as clinical studies or underway toward clinical trial status:

---

🧬 1. iPS-derived exosome clinical research (2025–2026)

A clinical study is underway in Japan to evaluate safety and potential efficacy of iPS cell-derived exosomes (tiny cell-derived particles) for cognitive, muscle, and immune function decline related to aging. This is an interventional randomized double-blind, placebo-controlled trial involving participants aged 50–80. JRCT

• Focus: iPS cell-derived exosomes

• Purpose: exploratory evaluation of effects on cognition/muscle/immune function

• Phase/Type: clinical research (not specified as drug phase)

• Timeline: Oct 2025 – Mar 2026 (estimated)

• Subjects: 45 participants JRCT

---

🫀 2. Heart muscle cell transplants using iPS cells

A Kyoto-based regenerative medicine startup iHeart Japan has conducted a clinical trial using a sheet of cardiac muscle cells derived from human iPS cells in a patient with dilated cardiomyopathy. Early reports indicate the patient has been discharged and is being monitored. The Japan Times

• Focus: iPS-derived cardiac muscle

• Condition: dilated cardiomyopathy

• Institution: Tokyo Women’s Medical University Hospital / Kyoto startup The Japan Times

---

🧠 3. Parkinson’s disease and neurodegeneration iPS clinical research

Japanese research groups have conducted Phase I/II clinical studies transplanting iPS-derived dopaminergic neurons into patients with Parkinson’s disease, showing safety and feasibility in early trials. National Institute of Health

• Focus: PD regenerative therapy with iPS cells

• Phase: I/II (early clinical trial)

• Institution: Kyoto University (investigator-initiated) National Institute of Health

---

👁️ 4. Retinal iPS/eye cell transplant research

Clinical research has been ongoing using human iPS cell-derived retinal pigment epithelium cells for wet age-related macular degeneration. Some early clinical research was initiated by institutions like Kobe City Eye Hospital. National Institute of Health

• Focus: retinal cells for macular degeneration

• Status: clinical research / early phase trials National Institute of Health

---

🧬 5. Other iPS-derived cell therapies in development

According to a regulatory summary of Japanese clinical research:

• Cartilage cell transplants (knee injury)

• Allogeneic iPS cardiomyocytes (dilated and ischemic heart disease)

• Anti-GPC3 CAR-NK cells (ovarian cancer)

• Corneal endothelial cells (bullous keratopathy)

• Platelet-producing cells (thrombocytopenia)
  These are clinical research trials and early stages reflecting ongoing efforts toward therapeutic application of iPS-derived cells. National Institute of Health

---

📌 Background context (why Japan leads in this area)

Japan’s focus on iPS cell research stems from the pioneering work of Shinya Yamanaka, Nobel laureate for developing iPS technology, which has accelerated both basic science and clinical applications of human cells in regenerative medicine. JPMA

The Japan Regenerative Medicine Project and research networks organized by AMED (Japan Agency for Medical Research and Development) support clinical translation of iPS/ES cell therapies from lab to patients. amed.go.jp

---

📍 Summary of Available Trials / Studies

Trial / Research	Focus	Status
iPS-derived exosome trial	Aging biomarker intervention	Active 2025–2026 JRCT
iHeart Japan heart cell transplant	iPS cardiac muscle	Reported trial The Japan Times
Parkinson’s cell therapy	Dopaminergic neurons	Phase I/II National Institute of Health
Retinal cell therapy	Retinal pigment epithelium	Early clinical research National Institute of Health
Multiple iPS/ES clinical research	Heart, cartilage, NK cells, cornea, etc.	Ongoing research list National Institute of Health

---

If you need direct registry links (e.g., jRCT or AMED trial pages) for any of these studies, let me know which one and I’ll pull them for you.